NEW YORK, Jan. 4, 2019 /PRNewswire/ -- S1 Biopharma, Inc. (S1) announced today that researchers will present an expandedanalysis of data from the company's Phase 2a clinical trial of Lorexys™ for the treatment of women with hypoactive sexual desire disorder (HSDD) based on the Patient Global Impression of Change (PGIC) scale. Robert E. Pyke, MD, PhD, president of Pykonsult, LLC, and Anita H. Clayton, MD, psychiatrist in the Department of Psychiatry & Neurobehavioral Sciences at the University of Virginia, will present the data in a poster presentation entitled, "Lorexys Phase 2a Results: Patient's Global Impression of Change (PGIC)," during the International Society for the Study of Women's Sexual Health (ISSWSH) and the International Society for Sexual Medicine (ISSM) Joint Meeting to be held March 7-10, 2019 at the Grand Hyatt Atlanta in Atlanta, GA.
The presentation will take place on Saturday, March 9, 2019 during the poster session from 6:00 p.m. to 7:30 p.m. EST.
Lorexys™ is an investigational oral, non-hormonal central nervous system therapy targeting HSDD in women, the most common type of female sexual dysfunction. The therapy is designed to restore the balance of key neurotransmitters in the brain - dopamine, serotonin and norepinephrine - that are known to regulate sexual inhibition and sexual excitation. The goal of the Phase 2a clinical study is to evaluate the safety, tolerability and pro-sexual efficacy of Lorexys™ as compared to monotherapy with bupropion, one of its constituent drugs.
About S1 Biopharma, Inc.
S1 Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the treatment of sexual dysfunction in both women and men. The company's development programs include first-in-class non-hormonal therapies designed to treat diminished sexual desire by restoring the natural balance of key neurotransmitters in the brain. The company's lead product candidate, Lorexys™, is currently positioned to advance to a Phase 2b clinical trial for the treatment of hypoactive sexual desire disorder (HSDD) in women. S1 Biopharma is evaluating partnerships, collaborations and out-licensing deals that will enable the company to rapidly advance its sexual dysfunction franchise as well as to accelerate the path to commercialization for its drug candidates in the U.S. and internationally. For more information, visit http://s1biopharma.com/ or follow S1 Biopharma on Facebook or Twitter (@s1biopharma).
Media Contact:Jenna IacurciBerry & Company Public RelationsTel: email@example.com
View original content:http://www.prnewswire.com/news-releases/s1-biopharma-announces-expanded-analysis-of-phase-2a-data-on-lorexys-for-treatment-of-hypoactive-sexual-desire-disorder-based-on-pgic-scale-to-be-presented-at-2019-isswshissm-joint-meeting-300772748.html
SOURCE S1 Biopharma, Inc.
Subscribe to our Free Newsletters!